To the Editor: Exposure to ultraviolet radiation is an important risk factor for melanoma but is also the principal means by which the body synthesizes vitamin D in the skin. Prior studies on the association between 25-OH-D levels and melanoma occurrence and prognosis have shown conflicting results. 1, 2 To gain further insight into the relationship between serum 25-OH-D levels and later development of melanoma, we conducted a nested case-control study in postmenopausal white women in the Women's Health Initiative Observation Study and the Population Architecture using Genomics and Epidemiology study, which selected 718 melanoma cases and 718 controls without melanoma. 3, 4 The protocol was approved by each participating institution's review board and all women provided written informed consent. 25-OH-D levels were measured by using liquid chromatographyemass spectrometry from stored serum samples taken at baseline. Multivariable conditional logistic regression models were used to evaluate the association between 25-OH-D levels and risk for melanoma. Cox proportional hazards regression was used to estimate hazard ratios for melanoma-specific mortality, which was adjudicated with medial records. Table I shows the baseline characteristics of the Women's Health Initiative participants. Women with higher 25-OH-D concentrations resided in geographic areas of higher sun exposure (in langleys) (P ¼ .003). On average, women who developed melanoma had a 2-ng/mL higher mean 25-OH-D level at baseline than the controls (27.2 ng/mL vs 25.1 ng/mL, P \ .0001). At the time of diagnosis, 53.5% of melanoma cases (n ¼ 381) were invasive and 46.5% (n ¼ 331) were in situ. In multivariable models (Table II) , women with 25-OH-D levels of 30 ng/mL or higher had a 1.59-fold higher risk for development of invasive and in situ melanoma compared with women with 25-OH-D levels of 20 ng/mL or lower (95% confidence interval [CI], 1.04-2.42; P \ .01). Women with 25-OH-D levels between 20.1 and 29.9 ng/mL had a 1.79-fold higher risk for development of melanoma compared with women with 25-OH-D levels of 20 ng/mL or lower (95% CI, 1.22-2.62).
Women with melanoma and 25-OH-D levels of 20 ng/mL or lower at baseline were 2.75 times more likely to die of melanoma than women with 25-OH-D levels between 20.1 and 29.9 ng/mL (95% CI 1.14-6.65; P ¼.025), but there was no significant relationship in death by melanoma when comparing women with 25-OH-D levels of 20 ng/mL or lower at baseline to women with 25-OH-D levels of 30 ng/mL or higher (hazard ratio, 1.43; 95% CI, 0.66-3.12; P ¼ .396). The lack of significant association in the 30 ng/mL or higher strata could be due to the smaller sample size in this group (Table I) .
In our study, higher serum 25-OH-D levels were associated with a greater risk for development of melanoma, which may be related to higher ultraviolet radiation exposure. In contrast, low 25-OH-D levels before melanoma diagnosis were associated with a higher risk for melanoma-related death. Because 25-OH-D levels are higher in more physically active, healthier individuals, it is possible that these levels are serving as a marker for overall health. 5 It is important to note, however, that the difference in 25-OH-D levels between the melanoma and control group was small (2 ng/mL) and of unclear physiologic significance.
Our data demonstrate the challenge of studying the association of vitamin D levels with melanoma risk, because the measurement of 25-OH-D level is confounded by sunlight exposure, which is a major risk factor for the development of melanoma. The cause-and-effect relationship between serum 25-OH-D level and melanoma incidence and prognosis is important to explore, and carefully designed clinical trials are needed. 
